Pik Eu Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pik Eu Chang has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- George Boon-Bee Goh
Department of Gastroenterology and Hepatology Singapore General Hospital Singapore Singapore
12 shared publications - Chee-Kiat Tan
Department of Gastroenterology and Hepatology Singapore General Hospital Singapore Singapore
11 shared publications - Hiang Keat Tan
Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore
5 shared publications Chee Kiat Tan
Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore
4 shared publications- Lai Wei
Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
3 shared publications - Wei Qiang Leow
Department of Anatomical Pathology, Singapore General Hospital, Singapore 169856, Singapore
3 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in JHEP Reports
Spleen stiffness to rule out high-risk varices in advanced chronic liver disease: an individual patient data meta-analysis
- 14 October 2026
- Published by Elsevier in JHEP Reports
Open AccessSpleen stiffness to rule out high-risk varices in advanced chronic liver disease: an individual patient data meta-analysis
- Open Access
- 22 May 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102236
A prospective cohort validation study of a multivariable algorithm ASAP for risk stratification of surveillance for hepatocellular carcinoma
- 22 May 2026
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102236
Open AccessA prospective cohort validation study of a multivariable algorithm ASAP for risk stratification of surveillance for hepatocellular carcinoma
- Open Access
- 26 March 2026
- Published by MDPI AG in Preprints.org
External Validation of The Hospital Frailty Risk Score (HFRS) to Identify Liver Cirrhosis Patients at Risk for Frailty Mortality: A Multi Centre Retrospective Cohort Study in Asians
Background/Objectives: Frailty is a well-established predictor of adverse outcomes in older adults and patients with chronic disease. The Hospital Frailty Risk Score (HFRS), derived from administrative ICD-10 data, was previously developed and validated in Western populations to identify frailty risk. This study aimed to validate the HFRS in an Asian cirrhotic population and evaluate its ability to predict mortality and hospital readmissions. Methods: Patients with liver cirrhosis and at least one hospital admission in 2018 from two tertiary public hospitals in Singapore were identified using ICD-10 codes. HFRS was calculated using a two-year lookback period according to Gilbert’s methodology. Patients were categorized as no risk (score = 0), low risk (score < 5), intermediate risk (5–15), or high risk (>15). Outcomes assessed included 30-day mortality, 30-day hospital readmission, and 2-year mortality, with follow-up until 31 December 2020. Multivariate logistic regression analysis was performed. Results: A total of 814 patients were included, of whom 629 (77.3%) had frailty-related ICD-10 codes. Increasing HFRS category was independently associated with worse outcomes. Compared with the reference group, 30-day mortality increased stepwise with frailty: low risk odds ratio (OR) 25.74 (95% CI 1.54–431.33, p = 0.02), intermediate risk OR 40.42 (95% CI 2.42–676.14, p = 0.01), and high risk OR 50.92 (95% CI 2.92–887.08, p < 0.01). Higher HFRS was also associated with increased 30-day readmission and 2-year mortality across all risk categories. Conclusions: Frailty-related diagnoses are significant independent predictors of mortality and hospital readmission in patients with liver cirrhosis. HFRS is a cost-effective and scalable tool using administrative data to identify high-risk patients and support clinical risk stratification.
- 26 March 2026
- Published by MDPI AG in Preprints.org
Open AccessExternal Validation of The Hospital Frailty Risk Score (HFRS) to Identify Liver Cirrhosis Patients at Risk for Frailty Mortality: A Multi Centre Retrospective Cohort Study in Asians
Background/Objectives: Frailty is a well-established predictor of adverse outcomes in older adults and patients with chronic disease. The Hospital Frailty Risk Score (HFRS), derived from administrative ICD-10 data, was previously developed and validated in Western populations to identify frailty risk. This study aimed to validate the HFRS in an Asian cirrhotic population and evaluate its ability to predict mortality and hospital readmissions. Methods: Patients with liver cirrhosis and at least one hospital admission in 2018 from two tertiary public hospitals in Singapore were identified using ICD-10 codes. HFRS was calculated using a two-year lookback period according to Gilbert’s methodology. Patients were categorized as no risk (score = 0), low risk (score < 5), intermediate risk (5–15), or high risk (>15). Outcomes assessed included 30-day mortality, 30-day hospital readmission, and 2-year mortality, with follow-up until 31 December 2020. Multivariate logistic regression analysis was performed. Results: A total of 814 patients were included, of whom 629 (77.3%) had frailty-related ICD-10 codes. Increasing HFRS category was independently associated with worse outcomes. Compared with the reference group, 30-day mortality increased stepwise with frailty: low risk odds ratio (OR) 25.74 (95% CI 1.54–431.33, p = 0.02), intermediate risk OR 40.42 (95% CI 2.42–676.14, p = 0.01), and high risk OR 50.92 (95% CI 2.92–887.08, p < 0.01). Higher HFRS was also associated with increased 30-day readmission and 2-year mortality across all risk categories. Conclusions: Frailty-related diagnoses are significant independent predictors of mortality and hospital readmission in patients with liver cirrhosis. HFRS is a cost-effective and scalable tool using administrative data to identify high-risk patients and support clinical risk stratification.
- 10 May 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (7) , 1818-1824
Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study
Background and Aim: Current hepatocellular carcinoma (HCC) surveillance strategy has its limitations, consequently delaying early detection. The GALAD model has been validated in retrospective studies, with two published cut‐off values yielding different sensitivities for HCCs of different etiologies. We evaluated the performance of GALAD model in HCC surveillance and determined the ideal cut‐off value for our cohort.Methods: Patients undergoing 6‐monthly HCC surveillance in Singapore General Hospital were recruited between December 2017–October 2018. Study serum specimens were prospectively collected and retrospectively tested using the μTASWako alpha‐fetoprotein (AFP), AFP‐L3, and protein induced by vitamin K antagonism‐II (PIVKA‐II) kits. GALAD score was calculated and compared with individual biomarkers using area under the curve (AUC) analysis. Published GALAD cut‐offs of −0.63 and −1.95 were compared for their performance in HCC detection.Results: There were 207 patients (median age 59 years, 55.1% males). Hepatitis B was the commonest etiology (72.9%). By February 2023, with a median follow‐up of 48.9 months, 20 patients had developed HCC. Eight patients developed HCC within 1 year from specimen collection. For HCC developing within 1 year, GALAD model detected HCC with an AUC of 0.84, greater than AFP (AUC 0.77), AFP‐L3 (AUC 0.60), and PIVKA‐II (AUC 0.67). GALAD at cut‐off −1.95 achieved sensitivity and specificity of 75% and 92.5% for HCCs detected within 1 year, superior to cut‐off −0.63 (sensitivity 12.5%, specificity 100%).Conclusion: In this prospective study of HCC surveillance, the GALAD model performed better than individual biomarkers. The cut‐off of −1.95 was more useful in our predominantly chronic hepatitis B cohort.
- 10 May 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (7) , 1818-1824
Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study
Background and Aim: Current hepatocellular carcinoma (HCC) surveillance strategy has its limitations, consequently delaying early detection. The GALAD model has been validated in retrospective studies, with two published cut‐off values yielding different sensitivities for HCCs of different etiologies. We evaluated the performance of GALAD model in HCC surveillance and determined the ideal cut‐off value for our cohort.Methods: Patients undergoing 6‐monthly HCC surveillance in Singapore General Hospital were recruited between December 2017–October 2018. Study serum specimens were prospectively collected and retrospectively tested using the μTASWako alpha‐fetoprotein (AFP), AFP‐L3, and protein induced by vitamin K antagonism‐II (PIVKA‐II) kits. GALAD score was calculated and compared with individual biomarkers using area under the curve (AUC) analysis. Published GALAD cut‐offs of −0.63 and −1.95 were compared for their performance in HCC detection.Results: There were 207 patients (median age 59 years, 55.1% males). Hepatitis B was the commonest etiology (72.9%). By February 2023, with a median follow‐up of 48.9 months, 20 patients had developed HCC. Eight patients developed HCC within 1 year from specimen collection. For HCC developing within 1 year, GALAD model detected HCC with an AUC of 0.84, greater than AFP (AUC 0.77), AFP‐L3 (AUC 0.60), and PIVKA‐II (AUC 0.67). GALAD at cut‐off −1.95 achieved sensitivity and specificity of 75% and 92.5% for HCCs detected within 1 year, superior to cut‐off −0.63 (sensitivity 12.5%, specificity 100%).Conclusion: In this prospective study of HCC surveillance, the GALAD model performed better than individual biomarkers. The cut‐off of −1.95 was more useful in our predominantly chronic hepatitis B cohort.
- Open Access
Validation of ICD‐10 Consensus Code Set for Cirrhosis Detection Using Electronic Health Records in an Asian Population
Background: Systematic identification of patients with cirrhosis through electronic healthcare records (EHRs) using ICD‐10 codes is essential for epidemiological research but is prone to discrepancies. We aim to validate and improve a recent consensus code set of nine ICD‐10 codes to identify cirrhosis in a multi‐ethnic Asian population.Methods: We applied an initial broad algorithm of 25 ICD‐10 codes related to cirrhosis and its complications to identify patients potentially with cirrhosis admitted to Singapore General Hospital in 2018 and confirmed true cirrhosis cases via manual EHR review. We evaluated the consensus code set's sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in identifying cirrhosis cases. We examined alternative code sets to improve cirrhosis identification and validated them in another local hospital.Results: One thousand, seven hundred thirty‐three patients potentially with cirrhosis were identified, with 937 (54.1%) confirmed. The median age at diagnosis was 71 years (IQR: 64–78), with 65.6% males, 75.2%/8.8%/9.3%/6.7% Chinese/Indians/Malays/Others, and 56.7% Child‐Pugh A. The main etiologies were chronic hepatitis B (29.5%) and metabolic dysfunction–associated steatotic liver disease (25.5%). The consensus code set demonstrated sensitivity/specificity/PPV/NPV of 76.1%/82.0%/83.3%/74.5%, respectively. We identified a set of 10 ICD‐10 codes (SingHealth Chronic Liver Disease Registry [SoLiDaRity]‐10) with sensitivity/specificity/PPV/NPV of 76.5%/84.8%/85.6%/75.4%, respectively, demonstrating an improved specificity versus the consensus code set (p = 0.001). External validation in another local hospital with 578 patients potentially with cirrhosis demonstrated improved sensitivity of the SoLiDaRity‐10 code set versus the consensus code set (p = 0.033) (sensitivity/specificity/PPV/NPV: 78.0%/93.6%/94.1%/76.4% vs. 76.2%/93.6%/94.0%/75.0%, respectively).Conclusions: While the consensus code set performs well in identifying patients with cirrhosis in a multi‐ethnic Asian population, we propose the improved SoLiDaRity‐10 code set.
Open AccessValidation of ICD‐10 Consensus Code Set for Cirrhosis Detection Using Electronic Health Records in an Asian Population
Background: Systematic identification of patients with cirrhosis through electronic healthcare records (EHRs) using ICD‐10 codes is essential for epidemiological research but is prone to discrepancies. We aim to validate and improve a recent consensus code set of nine ICD‐10 codes to identify cirrhosis in a multi‐ethnic Asian population.Methods: We applied an initial broad algorithm of 25 ICD‐10 codes related to cirrhosis and its complications to identify patients potentially with cirrhosis admitted to Singapore General Hospital in 2018 and confirmed true cirrhosis cases via manual EHR review. We evaluated the consensus code set's sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in identifying cirrhosis cases. We examined alternative code sets to improve cirrhosis identification and validated them in another local hospital.Results: One thousand, seven hundred thirty‐three patients potentially with cirrhosis were identified, with 937 (54.1%) confirmed. The median age at diagnosis was 71 years (IQR: 64–78), with 65.6% males, 75.2%/8.8%/9.3%/6.7% Chinese/Indians/Malays/Others, and 56.7% Child‐Pugh A. The main etiologies were chronic hepatitis B (29.5%) and metabolic dysfunction–associated steatotic liver disease (25.5%). The consensus code set demonstrated sensitivity/specificity/PPV/NPV of 76.1%/82.0%/83.3%/74.5%, respectively. We identified a set of 10 ICD‐10 codes (SingHealth Chronic Liver Disease Registry [SoLiDaRity]‐10) with sensitivity/specificity/PPV/NPV of 76.5%/84.8%/85.6%/75.4%, respectively, demonstrating an improved specificity versus the consensus code set (p = 0.001). External validation in another local hospital with 578 patients potentially with cirrhosis demonstrated improved sensitivity of the SoLiDaRity‐10 code set versus the consensus code set (p = 0.033) (sensitivity/specificity/PPV/NPV: 78.0%/93.6%/94.1%/76.4% vs. 76.2%/93.6%/94.0%/75.0%, respectively).Conclusions: While the consensus code set performs well in identifying patients with cirrhosis in a multi‐ethnic Asian population, we propose the improved SoLiDaRity‐10 code set.
- Open Access
- 13 September 2024
- Published by Journal of the ASEAN Federation of Endocrine Societies (JAFES) in Journal of the ASEAN Federation of Endocrine Societies
- Vol. 39 (2) , 54-60
The Glutamate-Serine-Glycine Index as a Biomarker to Monitor the Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease
Objective. Bariatric surgery effectively treats non-alcoholic fatty liver disease (NAFLD). The glutamate-serine-glycine (GSG) index has emerged as a non-invasive diagnostic marker for NAFLD, but its ability to monitor treatment response remains unclear. This study investigates the GSG index's ability to monitor NAFLD's response to bariatric surgery. Methodology. Ten NAFLD participants were studied at baseline and 6 months post-bariatric surgery. Blood samples were collected for serum biomarkers and metabolomic profiling. Hepatic steatosis [proton density fat fraction (PDFF)] and fibroinflammation (cT1) were quantified with multiparametric magnetic resonance imaging (mpMRI), and hepatic stiffness with magnetic resonance elastography (MRE). Amino acids and acylcarnitines were measured with mass spectrometry. Statistical analyses included paired Student’s t-test, Wilcoxon-signed rank test, and Pearson’s correlation. Results. Eight participants provided complete data. At baseline, all had hepatic steatosis (BMI 39.3 ± 5.6 kg/m2, PDFF ≥ 5%). Post-surgery reductions in PDFF (from 12.4 ± 6.7% to 6.2 ± 2.8%, p = 0.013) and cT1 (from 823.3 ± 85.4ms to 757.5 ± 41.6ms, p = 0.039) were significant, along with the GSG index (from 0.272 ± 0.03 to 0.157 ± 0.05, p = 0.001). Conclusion. The GSG index can potentially be developed as a marker for monitoring the response of patients with NAFLD to bariatric surgery.
- 13 September 2024
- Published by Journal of the ASEAN Federation of Endocrine Societies (JAFES) in Journal of the ASEAN Federation of Endocrine Societies
- Vol. 39 (2) , 54-60
Open AccessThe Glutamate-Serine-Glycine Index as a Biomarker to Monitor the Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease
Objective. Bariatric surgery effectively treats non-alcoholic fatty liver disease (NAFLD). The glutamate-serine-glycine (GSG) index has emerged as a non-invasive diagnostic marker for NAFLD, but its ability to monitor treatment response remains unclear. This study investigates the GSG index's ability to monitor NAFLD's response to bariatric surgery. Methodology. Ten NAFLD participants were studied at baseline and 6 months post-bariatric surgery. Blood samples were collected for serum biomarkers and metabolomic profiling. Hepatic steatosis [proton density fat fraction (PDFF)] and fibroinflammation (cT1) were quantified with multiparametric magnetic resonance imaging (mpMRI), and hepatic stiffness with magnetic resonance elastography (MRE). Amino acids and acylcarnitines were measured with mass spectrometry. Statistical analyses included paired Student’s t-test, Wilcoxon-signed rank test, and Pearson’s correlation. Results. Eight participants provided complete data. At baseline, all had hepatic steatosis (BMI 39.3 ± 5.6 kg/m2, PDFF ≥ 5%). Post-surgery reductions in PDFF (from 12.4 ± 6.7% to 6.2 ± 2.8%, p = 0.013) and cT1 (from 823.3 ± 85.4ms to 757.5 ± 41.6ms, p = 0.039) were significant, along with the GSG index (from 0.272 ± 0.03 to 0.157 ± 0.05, p = 0.001). Conclusion. The GSG index can potentially be developed as a marker for monitoring the response of patients with NAFLD to bariatric surgery.
- Open Access
MELD3.0 is superior to MELDNa and MELD for prediction of mortality in patients with cirrhosis: An external validation in a multi‐ethnic population
Background and Aim: The model for end‐stage liver disease (MELD) was updated to MELDNa and recently to MELD3.0 to predict survival of cirrhotic patients. We validated the prognostic performance of MELD3.0 and compared with MELDNa and MELD amongst cirrhotic inpatients.Methods: Demographical, clinical, biochemical, and survival data of cirrhotic inpatients in Singapore General Hospital (SGH) from 01 January 2018 to 31 December 2018, were studied retrospectively. Patients were followed up from first admission in 2018 until death or until 01 April 2023. Area under the receiver operating characteristic curves (AUROC) were computed for the discriminative effects of MELD3.0, MELDNa, and MELD to predict 30‐, 90‐, and 365‐day mortalities. AUROC was compared with DeLong's test. The cutoff MELD3.0 score for patients at high risk of 30‐day mortality was determined using Youden's Index. Survival curves of patients with MELD3.0 score above and below the cutoff were estimated with Kaplan–Meier method and compared with log‐rank analysis.Results: Totally 862 patients were included (median age 71.0 years [interquartile range, IQR: 64.0–79.0], 65.4% males, 75.8% Chinese). Proportion of patients with Child‐Turcotte‐Pugh classes A/B/C were 55.5%/35.5%/9.0%. Median MELD3.0/MELDNa/MELD scores were 12.2 (IQR: 8.7–18.3)/11.0 (IQR: 8.0–17.5)/10.3 (IQR: 7.8–15.0). Median time of follow‐up was 51.9 months (IQR: 8.5–59.6). The proportion of 30‐/90‐/365‐day mortalities was 5.7%/13.2%/26.9%. AUROC of MELD3.0/MELDNa/MELD in predicting 30‐, 90‐, and 365‐day mortalities, respectively, were 0.823/0.793/0.783, 0.754/0.724/0.707, 0.682/0.654/0.644 (P < 0.05). Optimal cutoff to predict 30‐day mortality was MELD3.0 > 19 (sensitivity = 67.4%, specificity = 82.4%). Patients with MELD3.0 > 19, compared with patients with MELD3.0 ≤ 19, had shorter median time to death (98.0 days [IQR: 28.8–398.0] vs 390.0 days [IQR: 134.3–927.5]), and higher proportion of 30‐day mortality (68.8% vs 43.0%) (P < 0.001).Conclusion: MELD3.0 performs better than MELDNa and MELD in predicting mortality in cirrhotic inpatients. MELD3.0 > 19 predicts higher 30‐day mortality.
Open AccessMELD3.0 is superior to MELDNa and MELD for prediction of mortality in patients with cirrhosis: An external validation in a multi‐ethnic population
Background and Aim: The model for end‐stage liver disease (MELD) was updated to MELDNa and recently to MELD3.0 to predict survival of cirrhotic patients. We validated the prognostic performance of MELD3.0 and compared with MELDNa and MELD amongst cirrhotic inpatients.Methods: Demographical, clinical, biochemical, and survival data of cirrhotic inpatients in Singapore General Hospital (SGH) from 01 January 2018 to 31 December 2018, were studied retrospectively. Patients were followed up from first admission in 2018 until death or until 01 April 2023. Area under the receiver operating characteristic curves (AUROC) were computed for the discriminative effects of MELD3.0, MELDNa, and MELD to predict 30‐, 90‐, and 365‐day mortalities. AUROC was compared with DeLong's test. The cutoff MELD3.0 score for patients at high risk of 30‐day mortality was determined using Youden's Index. Survival curves of patients with MELD3.0 score above and below the cutoff were estimated with Kaplan–Meier method and compared with log‐rank analysis.Results: Totally 862 patients were included (median age 71.0 years [interquartile range, IQR: 64.0–79.0], 65.4% males, 75.8% Chinese). Proportion of patients with Child‐Turcotte‐Pugh classes A/B/C were 55.5%/35.5%/9.0%. Median MELD3.0/MELDNa/MELD scores were 12.2 (IQR: 8.7–18.3)/11.0 (IQR: 8.0–17.5)/10.3 (IQR: 7.8–15.0). Median time of follow‐up was 51.9 months (IQR: 8.5–59.6). The proportion of 30‐/90‐/365‐day mortalities was 5.7%/13.2%/26.9%. AUROC of MELD3.0/MELDNa/MELD in predicting 30‐, 90‐, and 365‐day mortalities, respectively, were 0.823/0.793/0.783, 0.754/0.724/0.707, 0.682/0.654/0.644 (P < 0.05). Optimal cutoff to predict 30‐day mortality was MELD3.0 > 19 (sensitivity = 67.4%, specificity = 82.4%). Patients with MELD3.0 > 19, compared with patients with MELD3.0 ≤ 19, had shorter median time to death (98.0 days [IQR: 28.8–398.0] vs 390.0 days [IQR: 134.3–927.5]), and higher proportion of 30‐day mortality (68.8% vs 43.0%) (P < 0.001).Conclusion: MELD3.0 performs better than MELDNa and MELD in predicting mortality in cirrhotic inpatients. MELD3.0 > 19 predicts higher 30‐day mortality.
- 1 August 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (2) , 75-79
IR management of portal hypertension complications
- 1 August 2023
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 22 (2) , 75-79
IR management of portal hypertension complications
- Open Access
Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades
Background and Aims: Hepatocellular carcinoma (HCC) is one of the commonest causes of cancer‐related death worldwide. Whether gender is an independent factor for HCC survival is debatable. We studied the influence of gender on the clinical characteristics of HCC and on survival.Methods: The study cohort comprised patients with HCC seen in our department from 1988 to 2021. Clinical data were prospectively collected. We studied and compared demography, HCC characteristics, and survival between females and males. Survival analysis was censored on October 31, 2015.Results: There were 1716 HCC patients. 343 (20.0%) were females. Females were significantly older at diagnosis (median 69 vs 62 years, P < 0.001). More females were diagnosed via regular HCC surveillance (37.9% vs 29.6%, P = 0.003). Hence, as expected, females had less‐advanced HCC at diagnosis with smaller median tumor diameter (30 vs 39.5 mm, P = 0.038), lower frequency of portal vein tumor thrombus (19.4% vs 33.4%, P < 0.001), less distant metastases (7.7% vs 11%, P = 0.043), and earlier Barcelona Clinic Liver Cancer (BCLC) stages (0/A, 39.7% vs 28.4%, P < 0.001). On multivariable analysis, HCC diagnosis via surveillance but not female gender was an independent predictor of improved HCC survival.Conclusions: In this large cohort of multi‐ethnic Asian patients, females with HCC were significantly more adherent to surveillance and hence presented with less advanced HCC with correspondingly better overall survival than males. The gender difference in survival is likely due to females having better adherence to HCC surveillance. Surveillance to diagnose early‐stage HCC remains crucial in improving outcomes.
Open AccessGender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades
Background and Aims: Hepatocellular carcinoma (HCC) is one of the commonest causes of cancer‐related death worldwide. Whether gender is an independent factor for HCC survival is debatable. We studied the influence of gender on the clinical characteristics of HCC and on survival.Methods: The study cohort comprised patients with HCC seen in our department from 1988 to 2021. Clinical data were prospectively collected. We studied and compared demography, HCC characteristics, and survival between females and males. Survival analysis was censored on October 31, 2015.Results: There were 1716 HCC patients. 343 (20.0%) were females. Females were significantly older at diagnosis (median 69 vs 62 years, P < 0.001). More females were diagnosed via regular HCC surveillance (37.9% vs 29.6%, P = 0.003). Hence, as expected, females had less‐advanced HCC at diagnosis with smaller median tumor diameter (30 vs 39.5 mm, P = 0.038), lower frequency of portal vein tumor thrombus (19.4% vs 33.4%, P < 0.001), less distant metastases (7.7% vs 11%, P = 0.043), and earlier Barcelona Clinic Liver Cancer (BCLC) stages (0/A, 39.7% vs 28.4%, P < 0.001). On multivariable analysis, HCC diagnosis via surveillance but not female gender was an independent predictor of improved HCC survival.Conclusions: In this large cohort of multi‐ethnic Asian patients, females with HCC were significantly more adherent to surveillance and hence presented with less advanced HCC with correspondingly better overall survival than males. The gender difference in survival is likely due to females having better adherence to HCC surveillance. Surveillance to diagnose early‐stage HCC remains crucial in improving outcomes.
- Open Access
- 6 January 2023
- Published by Wolters Kluwer Health in Singapore Medical Journal
- Vol. 67 (Suppl 1) , S11-S16
Aetiology and clinical outcomes of non-cirrhotic portal hypertension in Singapore
- 6 January 2023
- Published by Wolters Kluwer Health in Singapore Medical Journal
- Vol. 67 (Suppl 1) , S11-S16
Open AccessAetiology and clinical outcomes of non-cirrhotic portal hypertension in Singapore